A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Ryazhenov, V. V. [1 ]
Gorokhova, S. G. [2 ]
Gorokhov, V [3 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
[2] Russian Med Acad Continuous Profess Educ, Moscow, Russia
[3] Res Clin Ctr JSC Russian Railways, Moscow, Russia
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.589
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV42
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [1] PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A487
  • [2] Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis
    Andersen, L. V.
    Vestergaard, P.
    Deichgraeber, P.
    Lindholt, J. S.
    Mortensen, L. S.
    Frost, L.
    HEART, 2008, 94 (12) : 1607 - 1613
  • [3] Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study
    Picard, Fabien
    Ducrocq, Gregory
    Danchin, Nicolas
    Falissard, Bruno
    Hanon, Olivier
    Mahe, Isabelle
    Touze, Emmanuel
    Steg, Philippe Gabriel
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2018, 111 (05) : 349 - 356
  • [4] Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
    Stevanovic, Jelena
    Pompen, Marjolein
    Le, Hoa H.
    Rozenbaum, Mark H.
    Tieleman, Robert G.
    Postma, Maarten J.
    PLOS ONE, 2014, 9 (08):
  • [5] Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
    Dzeshka, Mikhail S.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2661 - 2678
  • [6] Non-valvular atrial fibrillation and stroke prevention
    Hankey, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) : 234 - 239
  • [7] Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice
    Falissard, Bruno
    Picard, Fabien
    Mahe, Isabelle
    Hanon, Olivier
    Touze, Emmanuel
    Danchin, Nicolas
    Lamy, Francois-Xavier
    Ricci, Lea
    Steg, Philippe Gabriel
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2019, 112 (6-7) : 400 - 409
  • [8] Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation
    Yasuhiro Hamatani
    Hisashi Ogawa
    Kensuke Takabayashi
    Yugo Yamashita
    Daisuke Takagi
    Masahiro Esato
    Yeong-Hwa Chun
    Hikari Tsuji
    Hiromichi Wada
    Koji Hasegawa
    Mitsuru Abe
    Gregory Y. H. Lip
    Masaharu Akao
    Scientific Reports, 6
  • [9] Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation
    Hamatani, Yasuhiro
    Ogawa, Hisashi
    Takabayashi, Kensuke
    Yamashita, Yugo
    Takagi, Daisuke
    Esato, Masahiro
    Chun, Yeong-Hwa
    Tsuji, Hikari
    Wada, Hiromichi
    Hasegawa, Koji
    Abe, Mitsuru
    Lip, Gregory Y. H.
    Akao, Masaharu
    SCIENTIFIC REPORTS, 2016, 6
  • [10] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
12345